Hormone replacement therapy market to exceed US$ 27.8 Bn by 2032

Hormone replacement therapy (HRT) is predominantly used to relieve post-menopause symptoms

New Delhi: As per ESOMAR-certified market research and consulting firm, the global hormone replacement therapy market was valued at around US$ 15.2 Bn in 2021 and is anticipated to exhibit a CAGR of close to 5.7% over the forecast period (2022-2032).
Hormone replacement therapy (HRT) is predominantly used to relieve post-menopause symptoms. HRT replaces hormones that are low in levels as women approach menopause.
During menopause, several women experience painful symptoms such as vaginal dryness and hot flashes. Hormone therapy or menopausal hormone therapy, is considered as an efficient treatment option for menopausal symptoms as it balances the hormone levels in the body. On account of these factors, the demand for HRT is projected to surge during the forecast period.
In addition, demand for hormone replacement therapy increases with growing awareness related to biological drugs for treatment of cancer. The market for biologics and protein products has developed owing to innovations in analytics observed over the past two decades.
This is due to the advanced analytical techniques which allows an in-depth physicochemical comparison of complex protein molecules and protein drugs. This in turn helps in the research and development of new drugs and therapy.
As per ESOMAR-certified market research and consulting firm, the market presents high growth opportunities in emerging countries such as China and India. Emerging countries are focused upon improving their healthcare infrastructure due to increasing resources and large patient pool in these regions.
In addition, necessary medications are imported from developed regions due to the lack of several manufacturers in developing regions, which increases their cost. Hence, key players are expanding their manufacturing capacity to generate revenue from hormone replacement therapy.
Key Takeaways from Market Study
  • By therapy type, the estrogen replacement therapy segment is expected to hold over 37.8% market value share by the end of 2032.
  • By dosage form, oral tablets/capsules segment is leading with over 41.4% of market share by 2032.
  • By indication, menopause segment will exhibit robust growth at a CAGR of 5.4% over the assessment period.
  • By end-user, hospitals held the highest segment share in terms of the market share value of 55.3% in 2021.
  • North America is considered the leading region with a value share of 30.1% by the end of the forecast period, owing to the presence of larger number of CROs and CMOs in the U.S.
 “With increasing prevalence of autoimmune disorders and expenditure to accelerate R&D activities, the hormone replacement therapy market is expected to witness advancements over the forecast period,” says an analyst of Future Market Insights.
Market Competition
Companies are adopting strategies such as mergers and acquisitions to gain competitive edge. Leading manufacturers such as Eli Lilly and Company, AbbVie, and Endo International plc are also adopting these strategies to enhance their presence in the market
For instance:
  • In July 2021, Eli Lilly and Company acquired Protomer Technologies to identify and synthesize molecules, which can sense glucose or other endogenous modulators of protein activity.
  • In May 2020, AbbVie acquired Allergan plc, following the receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
  • In December 2020, Endo International plc acquired BioSpecifics Technologies Corp., which is a commercial-stage biopharmaceutical company.

These insights are based on a report on Hormone Replacement Therapy Market by Future Market Insights